HUMIRA is a prescription medicine used to treat adults with moderate to severe chronic plaque psoriasis who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.

The drug suppresses the immune system by blocking the activity of TNF. TNF is a protein produced naturally by the body's immune system. Some people with certain autoimmune diseases produce too much TNF. Humira is designed to stop tumor necrosis factor-α, or TNF, from attacking healthy cells.

TNF triggers inflammation as part of the body's normal immune system response, however too much TNF can attack normal, healthy body tissue and cause tissue damage. HUMIRA binds to TNF and neutralises the function of TNF by blocking its interaction with receptors.

It can vary. Some people notice Humira working as soon as 2 weeks after starting treatment. But some people take Humira for 4 months or longer before they notice significantly clearer skin. If you're not seeing any improvement in your symptoms after a few months of Humira treatment, talk with your doctor.

Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. These infections include active tuberculosis (TB), reactivation of latent TB, invasive fungal infections, and bacterial, viral and other infections due to opportunistic pathogens.

Humira has an average rating of 6.2 out of 10 from a total of 668 reviews on Drugs.com. 54% of reviewers reported a positive experience, while 33% reported a negative experience.

Through its savvy but legal exploitation of the U.S. patent system, Humira's manufacturer, AbbVie, blocked competitors from entering the market. For the next six years, the drug's price kept rising. Today, Humira is the most lucrative franchise in pharmaceutical history.

Humira contains the active drug adalimumab, which is a biologic medication. Biologics are medications made from living cells. Adalimumab belongs to a class of medications known as tumor necrosis factor (TNF) blockers. (A class of medications is a group of drugs that work in a similar way.)

HUMIRA is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps.

78% of HUMIRA-treated patients (n=99) achieved PASI 75 improvement at Week 16 vs 19% of placebo-treated patients (n=48).

The cost for Humira subcutaneous kit (40 mg/0.4 mL) is around $7,299 for a supply of 2 kits, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.

Humira (adalimumab) is a medication that is used over the long-term. Your doctor will check your medication at regular intervals to be sure staying on Humira is appropriate for you. Your dose for Humira can also vary and depends on the condition being treated. However, many patients stay on Humira for many years.

Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. These infections include active tuberculosis (TB), reactivation of latent TB, invasive fungal infections, and bacterial, viral and other infections due to opportunistic pathogens.

Studies show that people taking biologics like Humira have close to a two times higher risk for being diagnosed with a non-melanoma skin cancer (NMSC). Basal cell and squamous cell are the two main types. They're also the most common types of cancer in general.

The COVID-19 pandemic has had a profound impact on the best-selling pharmaceuticals, leading to shifts in the list with Pfizer and BioNTech's Comirnaty surpassing AbbVie's Humira for the No. 1 spot in 2021.

Even with insurance, the drug, made by AbbVie, can be quite expensive. There was no direct competition for years, mostly because the company protected the drug with a thicket of patents.